Three-dimensional solid polymeric foams and a microfluidic process to design them

Patent metadata

Field	Value
Publication number	US-11945930-B2
Application number	US-202017066815-A
Country	US
Kind code	B2
Filing date	Oct 9, 2020
Priority date	Oct 11, 2019
Publication date	Apr 2, 2024
Grant date	Apr 2, 2024

Abstract

Organic solid three-dimensional polymeric foams, a process for preparing the same, and use thereof, the foams includes a solid continuous phase and pores, wherein the foams have a pore size ranging from 50 nm to 200 μm and a volumetric fraction of the solid continuous phase is from 0.1 to 60%, with respect to the total volume of the foams, and a polydispersity index from 1 to 30%, the foams being ordered over a volume of at least 100 pores.

First claim

The invention claimed is:

1. A process of preparation of an organic solid three-dimensional polymeric foam comprising: a solid continuous phase and pores,
wherein said solid continues phase is a cross-linked organic polymer,
wherein said pores are separated by plateau borders, the meeting points of said plateau borders forming nodes,
said solid three-dimensional polymeric foam:
a pore size comprised from 50 nm to 100 μm,
a volumetric fraction of the solid continuous phase comprised from 0.1 to 60%, with respect to the total volume of the foam,
a polydispersity index comprised from 1 to 30%,

wherein said solid three-dimensional polymeric foam is ordered over a volume of at least 100 pores,
said process comprising:
a step A of microfluidic bubbling of a gas phase through a liquid phase comprising a cross-linkable organic polymer, a cross-linking agent, a solvent and optionally a stabilizing agent, to obtain an organic liquid three-dimensional polymeric foam comprising a liquid continuous phase and bubbles, and
a step B of cross-linking of said liquid three-dimensional polymeric foam comprising a liquid continuous phase and bubbles, to obtain an organic solid three-dimensional polymeric foam comprising a solid continuous phase and pores,
said solid continuous phase being derived from the liquid phase, and said pores being derived from the bubbles,
said step A of microfluidic bubbling being carried out at a temperature from 0° C. to lower than 15° C., said temperature being low enough to inhibit the cross-linking reaction,
said step B of cross-linking being carried out after the step A of microfluidic bubbling and at a temperature comprised from 30 to 100° C., said temperature being high enough to trigger the cross-linking reaction,
said step A of microfluidic bubbling and said step B of cross-linking being carried out in separate reactors, and
step A being carried out in reactor A at a temperature from 0° C. to lower than 15° C. and step B being carried out in reactor B.

2. The process according to claim 1 , wherein the size of the bubbles used during said step A of microfluidic bubbling is controlled by the flow-rates, or by the pressures of the gas and the liquid phases, by the formulation and by the characteristic dimension of reactor A,
said flow rates of the gas and the liquid phases being comprised from 10 nL/min to 10 L/min,
said pressures of the gas and the liquid phases being comprised from 10 mbar to 20 bar,
said flow-rates being optionally varied during step A of bubbling, leading to the formation of from 1 to 10 populations of pores, or of from 2 to 10 populations of pores, or 1 or 2 populations of pores, each population of pores having a distinct pore size and polydispersity index,
said pore size being comprised from 50 nm to 100 μm,
said polydispersity index being comprised from 1 to 30%.

3. The process according to claim 1 , comprising:
a step A of microfluidic bubbling of a gas phase through a liquid phase comprising a cross-linkable polymer, a cross-linking agent, a solvent and optionally a stabilizing agent, to obtain an organic liquid polymeric foam comprising a liquid continuous phase and bubbles, and
a step B of cross-linking of said liquid polymeric foam comprising a liquid continuous phase and bubbles, to obtain a first layer of solid polymeric foam comprising a solid continuous phase and pores in reactor B,
and
a sequence of leaving the previously prepared first layer of solid foam in reactor B, and repeating steps A and B to obtain a second layer of solid polymeric foam on top of the first layer of solid polymeric foam, thus increasing the total amount of the solid polymeric foam, to obtain a solid three-dimensional polymeric foam,
said step B of cross-linking being carried out in such a way that cross-linking is only partial, ensuring adhesion between the first and second layers, and
step A of said repeating steps A and B being optionally carried out using different reactors A, or using different microfluidic chips.

4. The process according to claim 1 , further comprising:
a step C of applying pressure to the liquid three-dimensional polymeric foam as obtained by step A, resulting in a compressed organic liquid three-dimensional polymeric foam, said pressure being comprised from 1.1 to 100 bar,

said pressure being applied in reactor B,
wherein the step B of cross-linking and the step C of applying pressure are optionally carried out simultaneously, resulting in simultaneous compression and cross-linking of said liquid three-dimensional polymeric foam, to obtain an organic solid three-dimensional foam.

5. The process according to claim 1 , wherein the cross-linkable organic polymer is chosen from:
biopolymers, or polysaccharides,
polyvinyl alcohols polylactic acids (PLA), Poly-L-Lactic acids (PLLA), poly(lactic-co-glycolic acids) (PLGA), polyethylene glycols (PEG),
polyacrylates (PA), polymethacrylates (PMA), Poly(methyl methacrylates) (PMMA), polystyrenes (PS), poly-N-vinylpyrrolidones (PVP), Polyethyleneglycol acrylates (PEGA), polyethyleneglycol methacrylates (PEGMA), polyethyleneglycol diacrylates (PEGDA), polyethyleneglycol dimethacrylates (PEGDMA),
or mixtures of said organic polymers,

and wherein the cross-linking agent is chosen from the group of:
glycerol-phosphate disodium salt, glyoxal, genipin, sodium tripolyphosphate (TPP), divinyl sulfone (DVS), calcium chloride (CaCl 2 )), calcium acetate, glutaraldehyde, polyaldehydes and butanediol glycidyl ether,
or mixtures of said cross-linking agents.

6. The process according to claim 1 , wherein the cross-linkable organic polymer is chitosan and the cross-linking agent is glyoxal.

7. The process according to claim 1 , wherein the stabilizing agent is a surfactant, chosen from the group consisting of:
sodium dodecyl sulfate, sodium laureth sulfate, ammonium lauryl sulfate, and sodium palmitate,
decyl glucoside, poloxamers, and polyethylene glycol-based surfactants, coco glycoside, lauryl glycoside, polysorbate-20, or cetyl alcohol, and lauryl alcohol,
quaternary ammonium salts,
cocamidopropyl betaine, sodium lauroamphoacetate, and sodium cocoyl glutamate.

8. The process according to claim 1 , wherein the liquid phase further comprises:
nanoparticles, or
an active pharmaceutical ingredient, or
a contrast agent, or
a dye,

said active pharmaceutical ingredient optionally comprising a radiotracer,
said nanoparticles, active pharmaceutical ingredient, contrast agent or dye being optionally coupled to a fluorophore.

9. The process according to claim 1 , wherein the liquid phase further comprises:
nanoparticles, chosen from the group of:
metal oxide nanoparticles, or titanium dioxide (TiO 2 ) or aluminum oxide (Al 2 O 3 ) nanoparticles,
metallic nanoparticles, or silver (Ag), gold (Au), iron (Fe), nickel (Ni), copper (Cu)
or

germanium (Ge) nanoparticles,
bi-metallic nanoparticles, or gallium arsenide (GaAs), lead telluride (PbTe), or iron platinum (FePt) nanoparticles,
tri-metallic nanoparticles, or aluminum gallium arsenide (Al x Ga 1-x As) nanoparticles,
ceramic nanoparticles, or silicon carbide (SiC) or tungsten carbide (WC) nanoparticles,
magnetic nanoparticles, or iron oxide (Fe 2 O 3 ) nanoparticles,
silica (SiO 2 ) nanoparticles,
polymeric nanoparticles,

or mixtures thereof,

or
an active pharmaceutical ingredient, chosen from the group of:
anti-inflammatory drugs, or diclofenac, ibuprofen, acetyl salicylic acid, or steroid based anti-inflammatory drugs,
anti-cancer drugs, or paclitaxel, docetaxel, or doxorubicin,
analgesics, or morphine,
antibiotics, or penicillin or sulfonamide antibiotics,

said active pharmaceutical

Assignees

• Paris Sciences Et Lettres
• Centre Nat Rech Scient
• Ecole Superieure Physique & Chimie Ind Ville De Paris

Inventors

• Maimouni Ilham
• Russo Maria
• Cossy Janine
• Tabeling Patrick

Classifications

• C08J9/35 Primary

  Composite foams, i.e. continuous macromolecular foams containing discontinuous cellular particles or fragments · CPC title

• C08J3/24

  Crosslinking, e.g. vulcanising, of macromolecules (mechanical aspects B29C35/00; crosslinking agents C08K) · CPC title

• C08J9/0061

  characterized by the use of several polymeric components · CPC title

• C08J2205/042

  Nanopores, i.e. the average diameter being smaller than 0,1 micrometer · CPC title

• C08J2205/044

  Micropores, i.e. average diameter being between 0,1 micrometer and 0,1 millimeter · CPC title